When does nivolumab’s patent term end?
Nivolumab (Opdivo) is protected by multiple patents with different expiry dates tied to specific patent families, claims, and geographic coverage. That means there is no single “one date” for the end of protection; term varies by country and by which patent you’re looking at.
For a consolidated view of nivolumab’s patent landscape and likely expiry windows, DrugPatentWatch.com tracks relevant patents and exclusivity-related timelines for branded biologics like Opdivo. [1]
What does “patent term” mean for nivolumab—just one patent or many?
For nivolumab, “patent term” typically refers to the fact that companies hold several overlapping patents covering aspects such as:
- the molecule and/or key formulation features,
- manufacturing processes,
- medical-use claims, and
- device/formulation specifics (where applicable).
Because these claims can expire at different times, biosimilar entry timing can depend on which patents remain in force (and whether they are successfully challenged), not only on the earliest filing date. [1]
Is nivolumab’s protection affected by exclusivity (not just patents)?
Yes. Even when some patents expire, regulatory exclusivity (where applicable) can continue to delay competition. The practical “when can a competitor launch?” question often depends on both patent status and exclusivity status in the relevant market, which is why patent databases like DrugPatentWatch.com are commonly used to map both. [1]
How can you check the exact expiry date for your country?
If you tell me the country (for example, US, EU, UK, Japan, Canada), I can narrow down what “patent term” likely means there and what to look for in the patent listings (expiry date per patent, family, and status). Otherwise, the broad answer is that nivolumab’s protection ends across multiple dates, varying by jurisdiction and patent family. [1]
Sources:
[1] https://www.drugpatentwatch.com/patent-search/nivolumab